Hussain M, et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO Congress 2019, abstract LBA12_PR.
Vaak specifieke DNA-afwijkingen bij atypische tumoren Lynch-syndroom
apr 2023 | Gynaecologische oncologie, Immuuntherapie, Maag-darm-leveroncologie